Literature DB >> 23493086

Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease.

Paul S Aisen, Bruno Vellas, Harald Hampel.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23493086     DOI： 10.1038/nrd3842-c1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  9 in total

1.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 2.  Testing the right target and right drug at the right stage.

Authors:  Reisa A Sperling; Clifford R Jack; Paul S Aisen
Journal:  Sci Transl Med       Date:  2011-11-30       Impact factor: 17.956

Review 3.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

4.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging.

Authors:  Christopher C Rowe; Kathryn A Ellis; Miroslava Rimajova; Pierrick Bourgeat; Kerryn E Pike; Gareth Jones; Jurgen Fripp; Henri Tochon-Danguy; Laurence Morandeau; Graeme O'Keefe; Roger Price; Parnesh Raniga; Peter Robins; Oscar Acosta; Nat Lenzo; Cassandra Szoeke; Olivier Salvado; Richard Head; Ralph Martins; Colin L Masters; David Ames; Victor L Villemagne
Journal:  Neurobiol Aging       Date:  2010-05-15       Impact factor: 4.673

5.  Sting of Alzheimer's failures offset by upcoming prevention trials.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2012-09       Impact factor: 84.694

6.  Down's syndrome and Alzheimer's disease: towards secondary prevention.

Authors:  Seth Ness; Michael Rafii; Paul Aisen; Michael Krams; Wayne Silverman; Husseini Manji
Journal:  Nat Rev Drug Discov       Date:  2012-09       Impact factor: 84.694

7.  A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.

Authors:  Thorlakur Jonsson; Jasvinder K Atwal; Stacy Steinberg; Jon Snaedal; Palmi V Jonsson; Sigurbjorn Bjornsson; Hreinn Stefansson; Patrick Sulem; Daniel Gudbjartsson; Janice Maloney; Kwame Hoyte; Amy Gustafson; Yichin Liu; Yanmei Lu; Tushar Bhangale; Robert R Graham; Johanna Huttenlocher; Gyda Bjornsdottir; Ole A Andreassen; Erik G Jönsson; Aarno Palotie; Timothy W Behrens; Olafur T Magnusson; Augustine Kong; Unnur Thorsteinsdottir; Ryan J Watts; Kari Stefansson
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Authors:  Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245
  9 in total
  29 in total

Review 1.  Amyloid β Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies.

Authors:  Jessica Nasica-Labouze; Phuong H Nguyen; Fabio Sterpone; Olivia Berthoumieu; Nicolae-Viorel Buchete; Sébastien Coté; Alfonso De Simone; Andrew J Doig; Peter Faller; Angel Garcia; Alessandro Laio; Mai Suan Li; Simone Melchionna; Normand Mousseau; Yuguang Mu; Anant Paravastu; Samuela Pasquali; David J Rosenman; Birgit Strodel; Bogdan Tarus; John H Viles; Tong Zhang; Chunyu Wang; Philippe Derreumaux
Journal:  Chem Rev       Date:  2015-03-19       Impact factor: 60.622

Review 2.  The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease.

Authors:  Bhumsoo Kim; Sarah E Elzinga; Rosemary E Henn; Lisa M McGinley; Eva L Feldman
Journal:  Neurobiol Dis       Date:  2019-07-23       Impact factor: 5.996

3.  Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.

Authors:  J Scott Roberts; Laura B Dunn; Gil D Rabinovici
Journal:  Neurodegener Dis Manag       Date:  2013

4.  Altered GluN2B NMDA receptor function and synaptic plasticity during early pathology in the PS2APP mouse model of Alzheimer's disease.

Authors:  Jesse E Hanson; Jean-Francois Pare; Lunbin Deng; Yoland Smith; Qiang Zhou
Journal:  Neurobiol Dis       Date:  2014-12-04       Impact factor: 5.996

5.  A new roadmap for drug development for Alzheimer's disease.

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini; Lon S Schneider; Luigi Ferrucci
Journal:  Nat Rev Drug Discov       Date:  2013-12-20       Impact factor: 84.694

6.  The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials.

Authors:  Julien Dumurgier; Jean-Louis Laplanche; Francois Mouton-Liger; Pauline Lapalus; Sandrine Indart; Magali Prévot; Katell Peoc'h; Jacques Hugon; Claire Paquet
Journal:  J Neurol       Date:  2014-04-12       Impact factor: 4.849

Review 7.  The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Jennifer Salazar; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2016-12-05       Impact factor: 21.566

Review 8.  What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?

Authors:  Robert E Becker; Mary V Seeman; Nigel H Greig; Debomoy K Lahiri
Journal:  Lancet Psychiatry       Date:  2015-08       Impact factor: 27.083

Review 9.  Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic.

Authors:  Harald Hampel; Sid E O'Bryant; José L Molinuevo; Henrik Zetterberg; Colin L Masters; Simone Lista; Steven J Kiddle; Richard Batrla; Kaj Blennow
Journal:  Nat Rev Neurol       Date:  2018-11       Impact factor: 42.937

Review 10.  Regulation of protein conformation by Pin1 offers novel disease mechanisms and therapeutic approaches in Alzheimer's disease.

Authors:  Jane A Driver; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Discov Med       Date:  2014-02       Impact factor: 2.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.